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Two mutations  affecting the K  end of the H-2  ~ haplotype have been reported: 
/-/-2  ha,  carried  by  a  congenic  line  B6.C-H-2  ha,  also  called  B6.C-H(zl)  and 
abbreviated  Hzl  (1),  and  H-2  ~,  present  in  a  congenic line  B6.M505  (abbrev. 
M505,  cf. ref. 2). The H-2  ba mutation has attracted  attention of immunologists 
because it is capable of eliciting  graft rejection (1),  mixed lymphocyte reaction 
(MLR,  cf. ref. 3), and cell-mediated lymphocytotoxicity (CML,  see ref. 3,  4)  in 
combination  with the parental  haplotype H-2  ~,  and yet the two haplotypes are 
serologically  indistinguishable.  The  H-2  ~  mutation  has  recently been  demon- 
strated  to behave the  same way (5,  6).  In this  respect,  it has been difficult to 
accommodate  the  two  mutations  into  the  prevailing  view  of  the  functional 
differentiation of the H-2 complex. Many investigators believe that the H-2K and 
H-2D gene products, in addition to inducing serologically detectable antibodies, 
cause skin graft rejection but are ineffective in eliciting MLR, which is thought to 
be an  affair of the I region. For the development of effective CML, cooperation 
between  the  K(D)  and  I  region  has  been  postulated  (7).  According  to  this 
concept, the two mutations should be either serologically detectable and should 
cause no MLR, or should be serologically identical  and should stimulate MLR; 
they should not cause CML. The fact that they are not serologically detectable 
and yet elicit MLR and CML could mean either that each of them affects more 
than  one  locus,  or  alternatively,  that  the  present  concept  of the  functional 
subdivision of the H-2 complex is an oversimplification. In this report we describe 
evidence that  the latter alternative  is probably correct. 
Materials  and  Methods 
Mice.  The breeding pairs of the Hzl and M505  strains were obtained through the courtesy of 
Doctors D.  W.  Bailey and I. K. Egorov, respectively. Breeders of the C57BL/6 (or B6)  strain were 
supplied to us by the Jackson Laboratories, Bar Harbor, Maine. All other mice were obtained from 
our colony at the University of Texas. 
Serological Tests.  Hemagglutination tests were performed according to the method of Stimpfling 
(8)  in  a  modification described previously  (9).  Cytotoxic test  in  microplates was carried out  as 
described elsewhere (10) using splenocytes as target cells and normal guinea pig serum as a source of 
complement, and estimating the percentages of killed cells by means of phase contrast microscope. 
Quantitative absorptions were performed by the techniques described by Snell et al.  (11).  Briefly, 
lymphocytes from spleen and lymph nodes were distributed into a series of five tubes in such a way 
that the first tube contained 8  ×  l0  s (or in some cases 32  ×  10 e)  cells, and the subsequent tubes 
doubling dilutions of the initial suspension. Antiserum was added to each tube in a volume that gave 
a  final concentration corresponding to that giving 80%  of dead cells in  a  regular titration of the 
antiserum. The mixtures were incubated for 30 min, then centrifuged and the supernates tested for 
residual cytotoxicity. The concentration of cells in the initial suspension was determined by three 
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independent hemocytometer counts. Each absorption was run in triplicate and each cytotoxic test in 
duplicate. 
Results 
Bailey et al. (1), as well as other investigators, made several attempts to produce 
alloantisera using the congenic pair of B6 and B6.C-H(zl), but failed. We failed to 
produce antibodies in  the following strain  combinations:  B6 --, M505,  M505 --* 
B6,  M505  -~  (B10  x  C3H)F~,  using  different  immunization  regimens  and  a 
variety of serological  tests.  We also failed to differentiate the H-2  ba and  H-2  ~ 
haplotypes  from  the  H-2  ~ haplotype  using  a  battery  of oligospecific  antisera 
against  known  H-2  antigens.  In  all  instances,  antigens  present  in  the  H-2  ~ 
haplotype were found to be present in the two mutant haplotypes, and vice versa. 
However, in tests involving antiserum  K-30,  a  slight quantitative  difference in 
cytotoxic reactivity was observed between H-2  b on the one hand and ba and bd on 
the other hand.  The suggested difference was then  explored in detail using the 
quantitative  absorption technique. 
Antiserum K-30 was produced in combination (B10.D2 × A)F~ anti-HTI or d/a 
anti-/and should contain antibodies against the private antigen controlled by the 
H-2K  b allele (antigen  H-2.33). It could also contain antibodies against non-H-2 
antigens;  however, since the critical strains used in our experiments were of the 
same genetic background, only H-2 antibodies could be detected. Theoretically, 
the  antiserum  could  contain  antibodies  against  the  /-region-associated  (Ia) 
antigens.  Since  the  Ia  antigens  are  expressed  strongly  on  one  population  of 
lymphocytes  (usually  B  cells),  the  antiserum  was  absorbed  with  different 
numbers of T cells (to remove H-2 antibodies) and then tested against B cells (to 
detect Ia antibodies), or vice versa. However, in all experiments absorption by T 
(B) cells always removed all activity against B (T) cells, suggesting that the only 
antibodies present in the antiserum were those against H-2 antigens. Panel test 
of the  antiserum  (Table  I)  revealed  presence  of two  antibodies,  one  against 
antigen  H-2.33  and  another  against  unidentified  antigen  shared  by  strains 
C57BL/10Sn(H-2~), B10.S(H-2  ~) and probably also DBA/1 (H-2q). Absorption by 
B10.S  cells removed the B10.S and  DBA/1  reactivity but did not significantly 
affect the B6, Hzl, or M505 reactivity. 
Quantitative  absorption  of antiserum  K-30  by lymphocytes  from  B6,  Hzl, 
M505,  and  B10.D2  strains  was  repeated  6  times,  always  with  similar  result: 
approximately 2.5 times more Hzl or M505 than B6 cells were required to reduce 
the cytotoxicity of the antiserum against B6 cells to 50% (Fig. 1). This effect was 
specific, since antibodies against antigen H-2.2, the private antigen of the H-2D  ~ 
gene unaffected by the two mutations, were absorbed to an equal extent by b, ba, 
and  bd cells (Fig. 2). 
Discussion 
These observations indicate  that  the anti-H-2.33 absorptive capacity of the  ba 
and  bd  cells  is  lower than  that  of the  b  cells.  The  decrease  in  the  absorptive 
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two  mutations  were  of  a  regulatory  type  and  as  such  merely  decreased  the 
content  of H-2.33  on the  cell surface;  second,  the  mutations  occurred  outside  of 
the  H-2.33  site  and  modified  this  site  only  indirectly.  The  first explanation  is 
contradicted  by  the  fact  that  both  mutations  elicit  graft  rejection,  MLR  and 
TABLE I 
Reactivity  of antiserum  K-30  PI/  (BIO.D2xA  )F~ anti-HTI  with 
panel  of cells 
Strain  H-2 haplotype 
Reactivity of antiserum* 
Unabs.  Abs. by B10.S 
B10.A  a  --  -- 
C57BL/10Sn  b  + + + +  + + + + 
B6-H-2  ba  ba  + + +  + + + 
B6.M505  bd  + + +  + + + 
B10.D2  d  --  -- 
B10.M  f  --  -- 
B10.D2(R103)  g3  --  -- 
B10.A(4R)  h4  --  -- 
B10.A(3R)  i3  + + + +  + + + + 
B10.A(5R)  i5  + + + +  + + + + 
B10.A(R107)  i7  + + + +  + + + + 
B10.A(R106)  ia  + + +  + + + 
B10.WB  ja  --  -- 
B10.BR  k  --  -- 
B10.AKM  m  --  -- 
DBA/1  q  + +  -- 
DA  qpl  --  -- 
B10.RIII(71NS)  r  --  -- 
B10.S  s  + + 
A.TL  tl  -- 
B10.S(7R)  t2  -- 
B10.HTT  t3  --  -- 
* + + + +  = 50% titer 132, maximum kill of 95-100%;  + + +  = 50% titer 116, 
maximum kill of 95-100%;  ++  =  50% titer 1:16,  maximum kill 50%;  -  = 
less than 10% dead cells at antiserum dilution of 1:12 or higher. 
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Fro.  1.  Absorption of antiserum K-30:(B10.D2 × A)F~ anti-HTI (anti H-2.33) by spleen and 
lymph node cells from B10.D2 (A--A), M505  (A--A) Hzl (O---O) and B6 (Q---Q) mice. 1130  KLEIN ET  AL.  BRIEF DEFINITIVE  REPORT 
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Fro.  2.  Absorption  of  antiserum  K-302:(B10.D2  ×  A)F~  anti-B10.A(2R)  (anti-H-2.2)  by 
spleen and lymph node cells from B10.M (A--A), M505 (A--A), Hzl (O--O) and B6 (0--0) 
mice. 
CML  when  tested  in  combination  with  the  H-2 ~  strain,  indicating that  the 
mutational change was qualitative rather than quantitative. Thus, the serologi- 
cal  observations  indicate  quantitative,  and  the  cellular  immunity  studies 
qualitative  alterations caused by the  two  mutations. It  seems  to  us  that the 
simplest way to reconcile these seemingly contradictory results is to postulate 
that  the  serologically  detectable  site  (recognized  by  B  cells)  and  the  site 
detectable by cellular reactions (recognized by T  cells) are located in different 
portions of the same molecule. The mutations occurred in the site detectable by 
cellular immunity and changed the conformation of the H-2  molecule in such a 
way that  it  lowered  the  capacity of the  serologically detectable  site  to  bind 
anti-H-2.33 antibodies (the change in the primary structure of the H-2  molecule 
affected the  cellular immunity site,  and  the  change  in  the  tertiary structure 
affected the serologically detectable site). Alternatively, one can postulate that 
in both H-2 ba and H-2 b~ two mutations occurred simultaneously in two different 
genes,  one  coding  for  the  serologically  detectable  antigens  and  another  for 
antigens  detected  by  cellular  immunity.  However,  such  an  event  is  highly 
unlikely in the case of point mutations. 
The findings on the H-2  mutations challenge the commonly held view that the 
serologically detectable H-2  antigens are identical with antigens eliciting cellular 
immunity. Such a view is probably a misconception (for discussion see ref. 6) and 
more likely the relationship between the two types of antigens can be interpreted 
in terms of hapten-carrier interaction (for discussion see ref. 12). 
The  absorption  data  indicate  that  both  the  H-2 b~  and  H-2 ~  mutations 
occurred in the H-2K b gene rather than in one of the genes located in the I region. 
From this observation two important conclusions can be drawn. First, the H-2K 
antigens  are  capable  of causing significant MLR;  second,  induction of CML 
across the H-2K  locus difference does not require simultaneous difference in the I 
region. These conclusions are supported by the findings with a third mutation, 
H-2 ~  (6);  they  contradict  the  hypothesis  of  SD-LD  polarization  of  major 
histocompatibility complexes (13),  as well as the hypothesis of specific K  and I 
region cooperation in the development of CML (7). 
While this work was being completed, a manuscript by Apt and co-workers (5) KLEIN  ET AL.  BRIEF  DEFINITIVE  REPORT  1131 
reached us, in which the authors report that absorption of d/a anti-/serum with 
M505 spleen cells did not clear for H-2  b and H-2  ~, and absorption with Hzl cells 
did not  clear for H-2  b and H-2  ~a  indicating  a  qualitative  serological difference 
between the three H-2 haplotypes.  The discrepancy between these results and 
the results reported here can probably be explained by the fact that Apt et al. 
used  only a  single cell dose in their absorption studies  and that this  dose was 
insufficient to remove completely all the cross-reactivity. 
Summary 
A  quantitative serological difference was found between strains Hzl and M505 
carrying mutant H-2 haplotypes ba and bd,  respectively, and the original strain 
B6(H-2O). The finding suggests that the mutations occurred in the H-2K  ~ gene, 
and together with data on MLR and CML challenges the current concept of H-2 
regions' involvement in immune reactions. 
We thank Jan Pickett and Lloyd Gaedke for technical assistance and Donna Scudday for help in 
preparing this manuscript. 
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